January 12, 2017
FDA warns about cancer drug
The Food and Drug Administration is warning consumers not to purchase or use PNC-27, a product promoted and sold through http://PNC27.com,…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
January 12, 2017
Celyad: First pancreatic cancer patient in its CAR-T NKR-2THINK trial in Belgium
Celyad has activated a second clinical site in Belgium for the , with the registration of a pancreatic cancer patient…
January 11, 2017
Eli Lilly, Merck expand collaboration against cancer
Eli Lilly and Merck have expand an existing immuno-oncology collaboration through a subsidiary to add a new study of Lilly’s…
January 11, 2017
Evgen Pharma gets positive DSMB review of SAS trial
Evgen Pharma’s anti-stress drug SFX-01, which is currently in its Phase II study has shown good results and it can proceed as planned.
January 11, 2017
ValiRx encouraged by initial trials of cancer drug study, expands to more sites
A clinical stage biotechnology company, ValiRX, said on Wednesday that its VAL201 personalised Phase l/II prostate cancer study brought positive results.
January 10, 2017
NeuroVive,Karolinska Institutet collaboration on mitochondrial myopathy treatment
NeuroVive Pharmaceutical AB, the mitochondrial medicine company, has signed collaboration agreement with Karolinska Institutet, Stockholm, Sweden, regarding development of the company’s…
January 10, 2017
Novo Nordisk’s diabetes drug available in Europe in the first half of 2017
European Commission has granted marketing authorisation for Novo Nordisk’s Fiasp for the treatment of diabetes in adults.
January 10, 2017
EPO OK’s Active Biotech’s patent for multiple myeloma treatment
The European Patent Office has decided to grant Active Biotech’s patent application covering tasquinimod for use in the treatment of…
January 10, 2017
Cumberland Pharmaceuticals to distribute Clinigen’s cancer treatment aid Totect in U.S.
Clinigen Group has made a deal with Cumberland Pharmaceuticals to market another product in the US, this time an oncology drug Totect (dexrazoxane hydrochloride).
January 9, 2017
Roche gets FDA’s priority review for Tecentriq to treat different type of bladder cancer
Roche said on Monday that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) for metastatic urothelial carcinoma (mUC).